Abstract
580 First-in-human, Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results From a Phase I Study of a Selective BRAF Inhibitor (BRAFi) RG7256 in Patients with BRAF V600-mutated Advanced Solid Tumors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have